Skip to content
HowShorted

Nektar Therapeutics short interest in 2021

In 2021, Nektar Therapeutics's disclosed short interest ran from 13.36% of shares outstanding on 15 Jan 2021 to 10.28% on 31 Dec 2021, a change of -3.08 percentage points. The year's high was 13.36% on 15 Jan 2021 and its low 8.73% on 15 Oct 2021, averaging 10.18% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.15 days on 15 Apr 2021. Full history: Nektar Therapeutics.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Nektar Therapeutics in 2021

2021 in figures

Start of year
13.36% (15 Jan 2021)
End of year
10.28% (31 Dec 2021)
Change
-3.08 pp
High
13.36% (15 Jan 2021)
Low
8.73% (15 Oct 2021)
Average
10.18%
Highest days to cover
30.15 (15 Apr 2021)
SEC filings marked
9

Every report in 2021

Nektar Therapeutics short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202113.36%27.05results (8-K)
29 Jan 202112.76%20.09
12 Feb 202111.80%13.72
26 Feb 202111.84%13.87results (8-K), 10-K filed
15 Mar 202111.12%20.56
31 Mar 202110.74%23.92
15 Apr 202110.97%30.15
30 Apr 202110.55%26.69
14 May 20219.93%17.08results (8-K), 10-Q filed
28 May 20219.89%25.66
15 Jun 202110.04%17.79
30 Jun 20219.96%17.75
15 Jul 20219.78%22.36
30 Jul 20219.78%26.19
13 Aug 20219.59%20.63results (8-K), 10-Q filed
31 Aug 20219.44%18.97
15 Sep 20218.96%21.83
30 Sep 20218.81%16.29
15 Oct 20218.73%17.05
29 Oct 20218.83%19.77
15 Nov 20219.12%9.24results (8-K), 10-Q filed
30 Nov 20218.75%10.28
15 Dec 20219.24%7.58
31 Dec 202110.28%3.83

See also: Nektar Therapeutics's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.